About Contact Us Careers
Sign In

CDK4/6 Inhibitor Drugs Market - Top Companies and Manufacturers

  • Report ID: 2533
  • Published Date: Jul 23, 2024
  • Report Format: PDF, PPT

· 
An Outline of the Global CDK 4/6 Inhibitor Drugs Market

  1. Market Definition
  2. Market Segmentation
  3. Industry Overview

·  Assumptions & Abbreviations

·  Research Methodology & Approach

  1. Research Process
  2. Primary Research
    1. Manufacturers
    2. Suppliers/Distributors
    3. End Users
  3. Secondary Research
  4. Market Size Estimation

·  Summary of the Report for Key Decision Makers

·  Forces of Market Constituents

  1. Factors/drivers impacting the growth of the market
  2. Market trends for better business practices

·  Key Market Opportunities for Business Growth

·  Major Roadblocks for the Market Growth

·  Regulatory Landscape

·  Industry Value Chain Analysis

·  Recent Developments in the Market

·  Impact of Covid-19

·  Epidemiology

·  Treatment Guidelines for Breast Cancer

·  Unmet Needs

·  Product Profiling

·  Drug pricing and Reimbursements

·  Comparative Drug Analysis

·  Drug Pipeline Analysis

·  Competitive Positioning

·  Competitive Model: A Detailed Inside View for Investors

  1. Company Market Share (2023)
  2. Business Profile of Key Enterprise
    1. Pfizer Inc.
    2. Novartis
    3. Eli Lilly and Company
    4. Jiangshu Hengrui Pharmaceuticals Co. Ltd.

·  Global CDK 4/6 Inhibitor Drugs Market Outlook

  1. Market Overview
  2. Market Revenue by Value (USD Million), and Compound Annual Growth Rate (CAGR)
  3. Year-on-Year (YoY) Growth Trend Analysis
  4. Global CDK 4/6 Inhibitor Drugs Market Outlook & Projections, Opportunity Assessment by Segment, 2023-2036, By Drug Type
    1. Palbociclib, Market Value (USD Million) and CAGR, 2023-2036F
    2. Ribociclib, Market Value (USD Million), and CAGR, 2023-2036F
    3. Abemaciclib, Market Value (USD Million), and CAGR, 2023-2036F
    4. Dalpiciclib, Market Value (USD Million), and CAGR, 2023-2036F
    5. Birociclib, Market Value (USD Million), and CAGR, 2023-2036F
    6. Lerociclib, Market Value (USD Million), and CAGR, 2023-2036F
    7. BPI 16350, Market Value (USD Million), and CAGR, 2023-2036F
    8. Others, Market Value (USD Million), and CAGR, 2023-2036F
  5. Global CDK 4/6 Inhibitor Drugs Market Outlook & Projections, Opportunity Assessment by Segment, 2023-2036, By Patient
    1. PreMenopause, Market Value (USD Million) and CAGR, 2023-2036F
    2. PostMenopausal, Market Value (USD Million) and CAGR, 2023-2036F
    3. Others, Market Value (USD Million) and CAGR,  2023-2036F
  6. Global CDK 4/6 Inhibitor Drugs Market Segmentation Analysis (2023-2036), By End User
    1. Hospitals, Market Value (USD Million) and CAGR, 2023-2036F
    2. Clinics, Market Value (USD Million) and CAGR, 2023-2036F
    3. Research Laboratories, Market Value (USD Million) and CAGR, 2023-2036F
    4. Retail Pharmacies, Market Value (USD Million) and CAGR, 2023-2036F
  7. Global CDK 4/6 Inhibitor Drugs Market Segmentation Analysis (2023-2036), By Geography
    1. North America, Market Value (USD Million), and CAGR, 2023-2036F
    2. Europe, Market Value (USD Million), and CAGR, 2023-2036F
    3. Asia Pacific, Market Value (USD Million), and CAGR, 2023-2036F
    4. Latin America, Market Value (USD Million), and CAGR, 2023-2036F
    5. Middle East & Africa, Market Value (USD Million), and CAGR, 2023-2036F

·  North America CDK 4/6 Inhibitor Drugs Market Outlook

  1. Market Overview
  2. Market Revenue by Value (USD Million), and Compound Annual Growth Rate (CAGR)
  3. Year-on-Year (YoY) Growth Trend Analysis
  4. North America CDK 4/6 Inhibitor Drugs Market Outlook & Projections, Opportunity Assessment by Segment, 2023-2036, By Drug Type
    1. Palbociclib, Market Value (USD Million), and CAGR, 2023-2036F
    2. Ribociclib, Market Value (USD Million), and CAGR, 2023-2036F
    3. Abemaciclib, Market Value (USD Million), and CAGR, 2023-2036F
    4. Dalpiciclib , Market Value (USD Million), and CAGR, 2023-2036F
    5. Birociclib, Market Value (USD Million), and CAGR, 2023-2036F
    6. Lerociclib, Market Value (USD Million), and CAGR, 2023-2036F
    7. BPI 16350, Market Value (USD Million), and CAGR, 2023-2036F
    8. Others, Market Value (USD Million), and CAGR, 2023-2036F
  5. North America CDK 4/6 Inhibitor Drugs Market Outlook & Projections, Opportunity Assessment by Segment, 2023-2036, By Patient
    1. PreMenopause, Market Value (USD Million) and CAGR, 2023-2036F
    2. PostMenopausal, Market Value (USD Million) and CAGR, 2023-2036F
    3. Others, Market Value (USD Million) and CAGR,  2023-2036F
  6. North America CDK 4/6 Inhibitor Drugs Market Segmentation Analysis (2023-2036), By End User
    1. Hospitals, Market Value (USD Million) and CAGR, 2023-2036F
    2. Clinics, Market Value (USD Million) and CAGR, 2023-2036F
    3. Research Laboratories, Market Value (USD Million) and CAGR, 2023-2036F
    4. Retail Pharmacies, Market Value (USD Million) and CAGR, 2023-2036F
  7. North America CDK 4/6 Inhibitor Drugs Market Segmentation Analysis (2023-2036), By Country
    1. US, Market Value (USD Million), and CAGR, 2023-2036F
    2. Canada, Market Value (USD Million), and CAGR, 2023-2036F

·  Europe CDK 4/6 Inhibitor Drugs Market Outlook

  1. Market Overview
  2. Market Revenue by Value (USD Million), and Compound Annual Growth Rate (CAGR)
  3. Year-on-Year (YoY) Growth Trend Analysis
  4. Europe CDK 4/6 Inhibitor Drugs Market Outlook & Projections, Opportunity Assessment by Segment, 2023-2036, By Drug Type
    1. Palbociclib, Market Value (USD Million), and CAGR, 2023-2036F
    2. Ribociclib, Market Value (USD Million), and CAGR, 2023-2036F
    3. Abemaciclib, Market Value (USD Million), and CAGR, 2023-2036F
    4. Dalpiciclib , Market Value (USD Million), and CAGR, 2023-2036F
    5. Birociclib, Market Value (USD Million), and CAGR, 2023-2036F
    6. Lerociclib, Market Value (USD Million), and CAGR, 2023-2036F
    7. BPI 16350, Market Value (USD Million), and CAGR, 2023-2036F
    8. Others, Market Value (USD Million), and CAGR, 2023-203
  5. Europe CDK 4/6 Inhibitor Drugs Market Outlook & Projections, Opportunity Assessment by Segment, 2023-2036, By Patient
    1. PreMenopause, Market Value (USD Million) and CAGR, 2023-2036F
    2. PostMenopausal, Market Value (USD Million) and CAGR, 2023-2036F
    3. Others, Market Value (USD Million) and CAGR,  2023-2036F
  6. Europe CDK 4/6 Inhibitor Drugs Market Segmentation Analysis (2023-2036), By End-User
    1. Hospitals, Market Value (USD Million) and CAGR, 2023-2036F
    2. Clinics, Market Value (USD Million) and CAGR, 2023-2036F
    3. Research Laboratories, Market Value (USD Million) and CAGR, 2023-2036F
    4. Retail Pharmacies, Market Value (USD Million) and CAGR, 2023-2036F
  7. Europe CDK 4/6 Inhibitor Drugs Market Segmentation Analysis (2023-2036), By Country
    1. UK, Market Value (USD Million), and CAGR, 2023-2036F
    2. Germany, Market Value (USD Million), and CAGR, 2023-2036F
    3. Italy, Market Value (USD Million), and CAGR, 2023-2036F
    4. France, Market Value (USD Million), and CAGR, 2023-2036F
    5. Spain, Market Value (USD Million), and CAGR, 2023-2036F
    6. Russia, Market Value (USD Million), and CAGR, 2023-2036F
    7. Netherlands, Market Value (USD Million), and CAGR, 2023-2036F
    8. Rest of Europe, Market Value (USD Million), and CAGR, 2023-2036F

·  Asia Pacific CDK 4/6 Inhibitor Drugs Market Outlook

  1. Market Overview
  2. Market Revenue by Value (USD Million), and Compound Annual Growth Rate (CAGR)
  3. Year-on-Year (YoY) Growth Trend Analysis
  4. Asia Pacific CDK 4/6 Inhibitor Drugs Market Outlook & Projections, Opportunity Assessment by Segment, 2023-2036, By Drug Type
    1. Palbociclib, Market Value (USD Million), and CAGR, 2023-2036F
    2. Ribociclib, Market Value (USD Million), and CAGR, 2023-2036F
    3. Abemaciclib, Market Value (USD Million), and CAGR, 2023-2036F
    4. Dalpiciclib , Market Value (USD Million), and CAGR, 2023-2036F
    5. Birociclib, Market Value (USD Million), and CAGR, 2023-2036F
    6. Lerociclib, Market Value (USD Million), and CAGR, 2023-2036F
    7. BPI 16350, Market Value (USD Million), and CAGR, 2023-2036F
    8. Others, Market Value (USD Million), and CAGR, 2023-203
  5. Asia Pacific CDK 4/6 Inhibitor Drugs Market Outlook & Projections, Opportunity Assessment by Segment, 2023-2036, By Patient
    1. PreMenopause, Market Value (USD Million) and CAGR, 2023-2036F
    2. PostMenopausal, Market Value (USD Million) and CAGR, 2023-2036F
    3. Others, Market Value (USD Million) and CAGR,  2023-2036F
  6. Asia Pacific CDK 4/6 Inhibitor Drugs Market Segmentation Analysis (2023-2036), By End-User
    1. Hospitals, Market Value (USD Million) and CAGR, 2023-2036F
    2. Clinics, Market Value (USD Million) and CAGR, 2023-2036F
    3. Research Laboratories, Market Value (USD Million) and CAGR, 2023-2036F
    4. Retail Pharmacies, Market Value (USD Million) and CAGR, 2023-2036F
  7. Asia Pacific CDK 4/6 Inhibitor Drugs Market Segmentation Analysis (2023-2036), By Country
    1. China, Market Value (USD Million), and CAGR, 2023-2036F
    2. India, Market Value (USD Million), and CAGR, 2023-2036F
    3. Japan, Market Value (USD Million), and CAGR, 2023-2036F
    4. South Korea, Market Value (USD Million), and CAGR, 2023-2036F
    5. Singapore, Market Value (USD Million), and CAGR, 2023-2036F
    6. Australia, Market Value (USD Million), and CAGR, 2023-2036F
    7. Rest of Asia-Pacific, Market Value (USD Million), and CAGR, 2023-2036F

·  Latin America CDK 4/6 Inhibitor Drugs Market Outlook

  1. Market Overview
  2. Market Revenue by Value (USD Million), and Compound Annual Growth Rate (CAGR)
  3. Year-on-Year (YoY) Growth Trend Analysis
  4. Latin America CDK 4/6 Inhibitor Drugs Market Outlook & Projections, Opportunity Assessment by Segment, 2023-2036, By Drug Type
    1. Palbociclib, Market Value (USD Million), and CAGR, 2023-2036F
    2. Ribociclib, Market Value (USD Million), and CAGR, 2023-2036F
    3. Abemaciclib, Market Value (USD Million), and CAGR, 2023-2036F
    4. Dalpiciclib , Market Value (USD Million), and CAGR, 2023-2036F
    5. Birociclib, Market Value (USD Million), and CAGR, 2023-2036F
    6. Lerociclib, Market Value (USD Million), and CAGR, 2023-2036F
    7. BPI 16350, Market Value (USD Million), and CAGR, 2023-2036F
    8. Others, Market Value (USD Million), and CAGR, 2023-203
  5. Latin America CDK 4/6 Inhibitor Drugs Market Outlook & Projections, Opportunity Assessment by Segment, 2023-2036, By Patient
    1. PreMenopause, Market Value (USD Million) and CAGR, 2023-2036F
    2. PostMenopausal, Market Value (USD Million) and CAGR, 2023-2036F
    3. Others, Market Value (USD Million) and CAGR,  2023-2036F
  6. Latin America CDK 4/6 Inhibitor Drugs Market Segmentation Analysis (2023-2036), By End-User
    1. Hospitals, Market Value (USD Million) and CAGR, 2023-2036F
    2. Clinics, Market Value (USD Million) and CAGR, 2023-2036F
    3. Research Laboratories, Market Value (USD Million) and CAGR, 2023-2036F
    4. Retail Pharmacies, Market Value (USD Million) and CAGR, 2023-2036F
  7. Latin America CDK 4/6 Inhibitor Drugs Market Segmentation Analysis (2023-2036), By Country
    1. Brazil, Market Value (USD Million), and CAGR, 2023-2036F
    2. Mexico, Market Value (USD Million), and CAGR, 2023-2036F
    3. Argentina, Market Value (USD Million), and CAGR, 2023-2036F
    4. Rest of Latin America, Market Value (USD Million), and CAGR, 2023-2036F

·  Middle East & Africa CDK 4/6 Inhibitor Drugs Market Outlook

  1. Market Overview
  2. Market Revenue by Value (USD Million), and Compound Annual Growth Rate (CAGR)
  3. Year-on-Year (YoY) Growth Trend Analysis
  4. Middle East & Africa CDK 4/6 Inhibitor Drugs Market Outlook & Projections, Opportunity Assessment by Segment, 2023-2036, By Drug Type
    1. Palbociclib, Market Value (USD Million), and CAGR, 2023-2036F
    2. Ribociclib, Market Value (USD Million), and CAGR, 2023-2036F
    3. Abemaciclib, Market Value (USD Million), and CAGR, 2023-2036F
    4. Dalpiciclib , Market Value (USD Million), and CAGR, 2023-2036F
    5. Birociclib, Market Value (USD Million), and CAGR, 2023-2036F
    6. Lerociclib, Market Value (USD Million), and CAGR, 2023-2036F
    7. BPI 16350, Market Value (USD Million), and CAGR, 2023-2036F
    8. Others, Market Value (USD Million), and CAGR, 2023-203
  5. Middle East & Africa CDK 4/6 Inhibitor Drugs Market Outlook & Projections, Opportunity Assessment by Segment, 2023-2036, By Patient
    1. PreMenopause, Market Value (USD Million) and CAGR, 2023-2036F
    2. PostMenopausal, Market Value (USD Million) and CAGR, 2023-2036F
    3. Others, Market Value (USD Million) and CAGR,  2023-2036F
  6. Middle East & Africa CDK 4/6 Inhibitor Drugs Market Segmentation Analysis (2023-2036), By End-User
    1. Hospitals, Market Value (USD Million) and CAGR, 2023-2036F
    2. Clinics, Market Value (USD Million) and CAGR, 2023-2036F
    3. Research Laboratories, Market Value (USD Million) and CAGR, 2023-2036F
    4. Retail Pharmacies, Market Value (USD Million) and CAGR, 2023-2036F
  7. Middle East & Africa CDK 4/6 Inhibitor Drugs Market Segmentation Analysis (2023-2036) , By Country
    1. GCC, Market Value (USD Million), and CAGR, 2023-2036F
    2. Israel, Market Value (USD Million), and CAGR, 2023-2036F
    3. South Africa, Market Value (USD Million), and CAGR, 2023-2036F
    4. Rest of Middle East & Africa, Market Value (USD Million), and CAGR, 2023-2036F

Companies Dominating the CDK4/6 Inhibitor Drugs Landscape

    • Pfizer Inc.
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Novartis AG
    • Eli Lilly and Company
    • Jiangsu Hengrui Pharmaceuticals Co., Ltd.
    • AstraZeneca plc
    • Celltrion, Inc
    • Merck & Co., Inc.
    • Halozyme Inc.
    • Sanofi
    • NATCO Pharma Limited
Browse Key Market Insights with Data Illustration:

In the News

  • In April 2021, Pfizer announced the acquisition of Amplyx Pharmaceuticals Inc., which is a privately held company dedicated to discovering medicines for severe and sometimes fatal illnesses affecting people with weakened immune systems.
  • In 2023, Novartis announced improved invasive survival assessment results from the pivotal Phase 3 NATALEE study, with a median follow-up of 33.3 months and 78.3% of patients completing Kiscal therapy. These results confirm the benefit observed in a previous interim analysis in patients with HR+/HER2- early stages II and III  breast cancer who received adjuvant Kisqari and nonsteroidal aromatase inhibitors. Patients had a 25.1% increased chance of malignant recurrence compared with typical endocrine therapy. Comparison of therapy (ET) and ET alone.

Author Credits:  Radhika Pawar


  • Report ID: 2533
  • Published Date: Jul 23, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

In the year 2024, the industry size of cdk4/6 inhibitor drugs is evaluated at USD 12.15 Billion.

The cdk4/6 inhibitor drugs market size was valued at USD 10.55 Billion in 2023 and is likely to exceed USD 79.41 Billion by the end of 2036, expanding at over 16.8% CAGR during the forecast period i.e., between 2024-2036. The growing cases of breast cancer and increasing advancement in drug development are some of the major factors anticipated to drive the growth of the CDK4/6 Inhibitor Drugs market.

North America industry is poised to dominate 69% revenue share by 2036, impelled by increasing number of clinical trials in the region.

Pfizer Inc., Novartis AG, Eli Lilly and Company, Jiangsu Hengrui Pharmaceuticals Co., Ltd., AstraZeneca plc, Celltrion, Inc, Merck & Co., Inc., Halozyme Inc., Sanofi, NATCO Pharma Limited
Inquiry Before Buying Request Free Sample

Copyright © 2024 Research Nester. All Rights Reserved

logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying
Inquiry Before Buying Request Free Sample